Clinical Trial Update: Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial (REVIVE) evaluating lenvatinib or regorafenib for advanced hepatocellular carcinoma after immunotherapy; the study status is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Stivarga (regorafenib)

Snippet

Sponsor: Asan Medical Center | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING